Posted by Michael Wonder on 05 Apr 2023
PHARMAC shares next steps in reviewing rule 8.1b
5 April 2023 - PHARMAC’s consultation on rule 8.1b of the Pharmaceutical Schedule has now closed.
“Rule 8.1b is a unique exception that means any medicine used to treat cancer in a paediatric setting is automatically funded without a PHARMAC assessment,” says PHARMAC's Chief Executive Sarah Fitt. “PHARMAC is looking at future use of this unique funding exception for children with cancer.”
All paediatric cancer treatments currently used will continue to be funded by PHARMAC, irrespective of what feedback received.
